Literature DB >> 33666169

Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys.

Daniel B Larremore1,2, Bailey K Fosdick3, Kate M Bubar4,5, Sam Zhang4, Stephen M Kissler6, C Jessica E Metcalf7, Caroline O Buckee8,9, Yonatan H Grad6.   

Abstract

Establishing how many people have been infected by SARS-CoV-2 remains an urgent priority for controlling the COVID-19 pandemic. Serological tests that identify past infection can be used to estimate cumulative incidence, but the relative accuracy and robustness of various sampling strategies have been unclear. We developed a flexible framework that integrates uncertainty from test characteristics, sample size, and heterogeneity in seroprevalence across subpopulations to compare estimates from sampling schemes. Using the same framework and making the assumption that seropositivity indicates immune protection, we propagated estimates and uncertainty through dynamical models to assess uncertainty in the epidemiological parameters needed to evaluate public health interventions and found that sampling schemes informed by demographics and contact networks outperform uniform sampling. The framework can be adapted to optimize serosurvey design given test characteristics and capacity, population demography, sampling strategy, and modeling approach, and can be tailored to support decision-making around introducing or removing interventions.
© 2021, Larremore et al.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; antibody; epidemiology; global health; infectious disease; microbiology; modeling; none; serology; uncertainty

Mesh:

Year:  2021        PMID: 33666169      PMCID: PMC7979159          DOI: 10.7554/eLife.64206

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.140


  27 in total

1.  Aggregated mobility data could help fight COVID-19.

Authors:  Caroline O Buckee; Satchit Balsari; Jennifer Chan; Mercè Crosas; Francesca Dominici; Urs Gasser; Yonatan H Grad; Bryan Grenfell; M Elizabeth Halloran; Moritz U G Kraemer; Marc Lipsitch; C Jessica E Metcalf; Lauren Ancel Meyers; T Alex Perkins; Mauricio Santillana; Samuel V Scarpino; Cecile Viboud; Amy Wesolowski; Andrew Schroeder
Journal:  Science       Date:  2020-03-23       Impact factor: 47.728

2.  Demographic patterns of blood donors and donations in a large metropolitan area.

Authors:  Beth H Shaz; Adelbert B James; Krista L Hillyer; George B Schreiber; Christopher D Hillyer
Journal:  J Natl Med Assoc       Date:  2011-04       Impact factor: 1.798

3.  Mathematical models used to inform study design or surveillance systems in infectious diseases: a systematic review.

Authors:  Sereina A Herzog; Stéphanie Blaizot; Niel Hens
Journal:  BMC Infect Dis       Date:  2017-12-18       Impact factor: 3.090

4.  Implications of Test Characteristics and Population Seroprevalence on "Immune Passport" Strategies.

Authors:  Daniel B Larremore; Kate M Bubar; Yonatan H Grad
Journal:  Clin Infect Dis       Date:  2021-05-04       Impact factor: 9.079

5.  Projecting social contact matrices in 152 countries using contact surveys and demographic data.

Authors:  Kiesha Prem; Alex R Cook; Mark Jit
Journal:  PLoS Comput Biol       Date:  2017-09-12       Impact factor: 4.475

6.  Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study.

Authors:  Silvia Stringhini; Ania Wisniak; Giovanni Piumatti; Andrew S Azman; Stephen A Lauer; Hélène Baysson; David De Ridder; Dusan Petrovic; Stephanie Schrempft; Kailing Marcus; Sabine Yerly; Isabelle Arm Vernez; Olivia Keiser; Samia Hurst; Klara M Posfay-Barbe; Didier Trono; Didier Pittet; Laurent Gétaz; François Chappuis; Isabella Eckerle; Nicolas Vuilleumier; Benjamin Meyer; Antoine Flahault; Laurent Kaiser; Idris Guessous
Journal:  Lancet       Date:  2020-06-11       Impact factor: 79.321

7.  Reductions in commuting mobility correlate with geographic differences in SARS-CoV-2 prevalence in New York City.

Authors:  Stephen M Kissler; Nishant Kishore; Malavika Prabhu; Dena Goffman; Yaakov Beilin; Ruth Landau; Cynthia Gyamfi-Bannerman; Brian T Bateman; Jon Snyder; Armin S Razavi; Daniel Katz; Jonathan Gal; Angela Bianco; Joanne Stone; Daniel Larremore; Caroline O Buckee; Yonatan H Grad
Journal:  Nat Commun       Date:  2020-09-16       Impact factor: 14.919

8.  Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period.

Authors:  Stephen M Kissler; Christine Tedijanto; Yonatan H Grad; Marc Lipsitch; Edward Goldstein
Journal:  Science       Date:  2020-04-14       Impact factor: 47.728

9.  Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years.

Authors:  Chadi M Saad-Roy; Caroline E Wagner; Rachel E Baker; Sinead E Morris; Jeremy Farrar; Andrea L Graham; Simon A Levin; Michael J Mina; C Jessica E Metcalf; Bryan T Grenfell
Journal:  Science       Date:  2020-09-21       Impact factor: 47.728

10.  Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India.

Authors:  Anup Malani; Daksha Shah; Gagandeep Kang; Gayatri Nair Lobo; Jayanthi Shastri; Manoj Mohanan; Rajesh Jain; Sachee Agrawal; Sandeep Juneja; Sofia Imad; Ullas Kolthur-Seetharam
Journal:  Lancet Glob Health       Date:  2020-11-13       Impact factor: 26.763

View more
  20 in total

1.  Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: A population-based serosurvey.

Authors:  Lara E Coelho; Paula M Luz; Débora C Pires; Emilia M Jalil; Hugo Perazzo; Thiago S Torres; Sandra W Cardoso; Eduardo M Peixoto; Sandro Nazer; Eduardo Massad; Mariângela F Silveira; Fernando C Barros; Ana T R Vasconcelos; Carlos A M Costa; Rodrigo T Amancio; Daniel A M Villela; Tiago Pereira; Guilherme T Goedert; Cleber V B D Santos; Nadia C P Rodrigues; Beatriz Grinsztejn; Valdilea G Veloso; Claudio J Struchiner
Journal:  Lancet Reg Health Am       Date:  2022-07-30

2.  Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020.

Authors:  Cesar A Lopez; Clark H Cunningham; Sierra Pugh; Katerina Brandt; Usaphea P Vanna; Matthew J Delacruz; Quique Guerra; D Ryan Bhowmik; Samuel J Goldstein; Yixuan J Hou; Margaret Gearhart; Christine Wiethorn; Candace Pope; Carolyn Amditis; Kathryn Pruitt; Cinthia Newberry-Dillon; John L Schmitz; Lakshmanane Premkumar; Adaora A Adimora; Ralph S Baric; Michael Emch; Ross M Boyce; Allison E Aiello; Bailey K Fosdick; Daniel B Larremore; Aravinda M de Silva; Jonathan J Juliano; Alena J Markmann
Journal:  mSphere       Date:  2022-05-19       Impact factor: 5.029

3.  SARS-CoV-2 seropositivity and COVID-19 among 5 years-old Amazonian children and their association with poverty and food insecurity.

Authors:  Marcelo U Ferreira; Isabel Giacomini; Priscila M Sato; Barbara H Lourenço; Vanessa C Nicolete; Lewis F Buss; Alicia Matijasevich; Marcia C Castro; Marly A Cardoso
Journal:  PLoS Negl Trop Dis       Date:  2022-07-18

4.  Real-time seroprevalence and exposure levels of emerging pathogens in infection-naive host populations.

Authors:  Francesco Pinotti; José Lourenço; Uri Obolski; Paul Wikramaratna; Marta Giovanetti; Robert Paton; Paul Klenerman; Craig Thompson; Sunetra Gupta
Journal:  Sci Rep       Date:  2021-03-12       Impact factor: 4.379

5.  Serological Tests in the Detection of SARS-CoV-2 Antibodies.

Authors:  Kissy Guevara-Hoyer; Jesús Fuentes-Antrás; Eduardo De la Fuente-Muñoz; Antonia Rodríguez de la Peña; Marcos Viñuela; Noemí Cabello-Clotet; Vicente Estrada; Esther Culebras; Alberto Delgado-Iribarren; Mercedes Martínez-Novillo; Maria José Torrejón; Rebeca Pérez de Diego; Miguel Fernández-Arquero; Alberto Ocaña; Pedro Pérez-Segura; Silvia Sánchez-Ramón
Journal:  Diagnostics (Basel)       Date:  2021-04-09

6.  Model-informed COVID-19 vaccine prioritization strategies by age and serostatus.

Authors:  Kate M Bubar; Kyle Reinholt; Stephen M Kissler; Marc Lipsitch; Sarah Cobey; Yonatan H Grad; Daniel B Larremore
Journal:  Science       Date:  2021-01-21       Impact factor: 47.728

7.  SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa.

Authors:  Jackie Kleynhans; Stefano Tempia; Nicole Wolter; Anne von Gottberg; Jinal N Bhiman; Amelia Buys; Jocelyn Moyes; Meredith L McMorrow; Kathleen Kahn; F Xavier Gómez-Olivé; Stephen Tollman; Neil A Martinson; Floidy Wafawanaka; Limakatso Lebina; Jacques D du Toit; Waasila Jassat; Mzimasi Neti; Marieke Brauer; Cheryl Cohen
Journal:  Emerg Infect Dis       Date:  2022-03-23       Impact factor: 16.126

8.  Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity.

Authors:  Hannah Clapham; James Hay; Isobel Routledge; Saki Takahashi; Marc Choisy; Derek Cummings; Bryan Grenfell; C Jessica E Metcalf; Michael Mina; Isabel Rodriguez Barraquer; Henrik Salje; Clarence C Tam
Journal:  Emerg Infect Dis       Date:  2020-06-16       Impact factor: 6.883

9.  Disparities in SARS-CoV-2 seroprevalence among individuals presenting for care in central North Carolina over a six-month period.

Authors:  Cesar A Lopez; Clark H Cunningham; Sierra Pugh; Katerina Brandt; Usaphea P Vanna; Matthew J Delacruz; Quique Guerra; Samuel Jacob Goldstein; Yixuan Jacob Hou; Margaret Gearhart; Christine Wiethorn; Candace Pope; Carolyn Amditis; Kathryn Pruitt; Cinthia Newberry-Dillon; John Schmitz; Lakshmanane Premkumar; Adaora A Adimora; Michael Emch; Ross Boyce; Allison E Aiello; Bailey K Fosdick; Daniel B Larremore; Aravinda M de Silva; Jonathan J J Juliano; Alena J Markmann
Journal:  medRxiv       Date:  2021-03-30

10.  Dynamics of behavior change in the COVID world.

Authors:  Cristina Moya; Patricio Cruz Y Celis Peniche; Michelle A Kline; Paul E Smaldino
Journal:  Am J Hum Biol       Date:  2020-08-23       Impact factor: 2.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.